Administration Over the past 16 years, the UNC Lineberger's administrative responsibilities have grown dramatically. Physical space has doubled. Dollars directly administered have increased eight-fold from $15.1 million in 1993 to $127.3 million in 2009 -2010 (including the Center's $50M/year University Cancer Research Fund). Over the next five years the Center will continue to grow in space, funding, and personnel. Growth will follow a Research Strategic Plan that proposes continued recruitment, new research initiatives. and development/expansion of core facilities. In all these efforts, the UNC Lineberger must continue to develop and improve its administrative, technology, and communication infrastructure/operation to facilitate cancer research. Cancer Center Administration (62 FTE. $4 million/year) supports the research activities of all 295 members. Administration provides direct grant, fiscal, and other administrative services to 93 Cancer Center members and 18 core facilities. Administrative support includes: laboratory, office, and conference space;common equipment;grant and fiscal management, human resources and other administrative services, computing infrastructure / networking, communications. and imaging / printing / web services. Center support alos includes In addition, the Center provides support by organizing recruitment, developmental pilot funding, seminars, symposia, and retreats. For Year 36, the Center requests a committed level of $489,049 to support 5.80 FTEs plus costs for supplies, travel, and other operational expenses. The proposed Year 36 budget is approximately 3% higher than the current budget. The requested CCSG Administration budget represents 12.5% of the UNC Lineberger's total Administration budget and 8% of the overall CCSG budget request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594121
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$346,647
Indirect Cost
$66,182
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Joseph, Sarah B; Arrildt, Kathryn T; Sturdevant, Christa B et al. (2015) HIV-1 target cells in the CNS. J Neurovirol 21:276-89
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21
Blazer, Marlo; Wu, Christina; Goldberg, Richard M et al. (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22:1153-9
Knight, E R W; Patel, E Y; Flowers, C A et al. (2015) ASC deficiency suppresses proliferation and prevents medulloblastoma incidence. Oncogene 34:394-402
Dellon, Evan S; Speck, Olga; Woodward, Kimberly et al. (2015) Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol 28:383-90
Qi, Qibin; Kilpeläinen, Tuomas O; Downer, Mary K et al. (2014) FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals. Hum Mol Genet 23:6961-72
Jha, Deepak Kumar; Strahl, Brian D (2014) An RNA polymerase II-coupled function for histone H3K36 methylation in checkpoint activation and DSB repair. Nat Commun 5:3965
Guo, Shutao; Lin, C Michael; Xu, Zhenghong et al. (2014) Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996-5009
Clark, Martha A; Goheen, Morgan M; Spidale, Nicholas A et al. (2014) RBC barcoding allows for the study of erythrocyte population dynamics and P. falciparum merozoite invasion. PLoS One 9:e101041
Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra et al. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57:7031-41

Showing the most recent 10 out of 292 publications